Skip to main
MMED

MMED Stock Forecast & Price Target

MMED Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 42%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Minimed Group is positioned for growth with its diverse portfolio and strong partnerships, as well as its recent spin-off from Medtronic and new leadership, leading to increased profitability. Despite potential competition and delays in product launches, MMED's undervalued stock and strong revenue growth make it a good investment opportunity, especially when compared to other positively-rated companies in the industry with varying price targets.

Bears say

Minimed Group is the leader in traditional, tubed insulin pumps and also offers continuous glucose monitors, smart insulin pens, and other consumables. However, there are several risks to the downside that could impact the growth and profitability of the company, such as competitive headwinds, limited traction from new product launches, and securing favorable contracts with pharmacies. Additionally, any delay to its planned summer 2027 launch of its FIT patch pump could push prospective patients towards competing systems. Furthermore, Abbott Labs' exclusive third-party supply of MiniMed's products and a larger than expected GLP-1 impact on progression to insulin dependence could also slow growth. With the company still in the process of separating from Medtronic and standing up standalone functions, it is still early to fully understand its margin ramp, but MMED is looking to differentiate itself by owning every piece of its insulin delivery and sensing system, making it an easier sell to prescribers and patients. However, the business will be prone to Osborne effect with its FIT patch pump in FY28 given the last year's dip in shipments with the Flex platform. Nevertheless, MMED's product portfolio reinforces its positioning in the T2 IIT population, with the Fit patch pump providing greater insulin capacity and extended wear. The company also has a clean balance

MMED has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 42% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiniMed Group Inc (MMED) Forecast

Analysts have given MMED a Buy based on their latest research and market trends.

According to 12 analysts, MMED has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiniMed Group Inc (MMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.